BMC Rheumatology最新文献

{"title":"A six-month weight loss intervention is associated with significant changes in serum biomarkers related to inflammation, bone and cartilage metabolism in obese patients with psoriatic arthritis and matched controls.","authors":"Linda Torres, Charlotte A Jonsson, Björn Eliasson, Helena Forsblad-d'Elia, Anton J Landgren, Annelie Bilberg, Inger Gjertsson, Ingrid Larsson, Eva Klingberg","doi":"10.1186/s41927-025-00511-0","DOIUrl":"10.1186/s41927-025-00511-0","url":null,"abstract":"<p><strong>Background: </strong>Obesity is highly overrepresented in patients with psoriatic arthritis (PsA) and associated with increased disease activity and inferior treatment outcome. We have previously reported in 41 patients with PsA and body mass index (BMI) ≥ 33 kg/m² that weight loss treatment with Very Low Energy Diet (VLED) resulted in a median weight loss of 18,6% and concomitantly a significant improvement in C-reactive protein (CRP) and disease activity at six months (M6). This sub-study analyzes the effects on serum biomarkers associated with inflammation, bone and cartilage metabolism in the same PsA patients and matched controls.</p><p><strong>Methods: </strong>Patients and controls received VLED treatment (640 kcal/day) during 12-16 weeks depending on baseline (BL) BMI < 40 or ≥ 40 kg/m², followed by an energy restricted diet. Serum was collected at BL and M6, and biomarkers were measured with Magnetic Luminex^® Assays and enzyme-linked immunosorbent assay (ELISA). Nonparametric statistics and paired comparison tests were used.</p><p><strong>Results: </strong>In the PsA patients, the following proteins were significantly reduced at M6 as compared to BL: hepatocyte growth factor (HGF) (median (first-third quartile) 327.9 (250.3-413.6) pg/mL vs. 271.3 (206.9-331.0) pg/mL, p < 0.01), vascular endothelial growth factor (VEGF) (79.6 (55.9-113.5) pg/mL vs. 69.6 (53.1-105.3) pg/mL, p = 0.01), B-cell activating factor (BAFF) (794.4 (716.4-868.3) pg/mL vs. 674.6 (613.2-790.5) pg/mL, p = 0.01) and cartilage oligomeric matrix protein (COMP) (266.1 (209.9-366.0) ng/mL vs. 217.0 (156.0-272.0) ng/mL, p < 0.01), whereas carboxyterminal telopeptide of type-1 collagen (CTX-1) was significantly increased (268.0 (196.0-378.5) pg/mL vs. 508.0 (350.0-640.0) pg/mL, p < 0.01). Similar results were found in the control group.</p><p><strong>Conclusions: </strong>Weight loss was associated with reduced levels of serum biomarkers related to inflammation and cartilage degradation, and increased biomarkers for bone resorption. The study supports the strong relationship between obesity, inflammation, bone and cartilage metabolism, identifying BMI as a possible confounder for biomarker levels.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT02917434, registered on September 21, 2016, retrospectively registered.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"58"},"PeriodicalIF":2.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12100911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatic? A diagnostic decision support tool for individuals suspecting rheumatic diseases: Mixed-methods usability and acceptability study.","authors":"Stefan Jakobi, Katharina Boy, Magali Wagner, Susann May, Alp Temiz, Anna-Maria Liphardt, Elizabeth Araujo, Loreto Carmona, Rachel Knevel, Georg Schett, Johannes Knitza, Felix Muehlensiepen, Harriet Morf","doi":"10.1186/s41927-025-00507-w","DOIUrl":"10.1186/s41927-025-00507-w","url":null,"abstract":"<p><strong>Background: </strong>The early diagnosis of inflammatory rheumatic diseases (IRDs) is of paramount importance in order to prevent irreversible damage to joints and to optimize treatment outcomes. Nevertheless, conventional care pathways frequently entail diagnostic delays spanning several months. Symptom checkers (SCs) have the potential to provide a solution by offering validated symptom assessments, improving triage systems and expediting diagnostic evaluations. The objective of this mixed-methods study is to assess the usability and acceptability of the SC Rheumatic? among individuals with suspected rheumatic diseases.</p><p><strong>Methods: </strong>A total of 105 individuals with suspected IRDs who were newly presenting at an outpatient rheumatology clinic completed the Rheumatic? symptom checker and an evaluation questionnaire. The questionnaire comprised the System Usability Scale (SUS) and Net Promoter Score (NPS). Additionally, 14 participants were interviewed by telephone in order to gain further insights through the qualitative method.</p><p><strong>Results: </strong>The Rheumatic? symptom checker received a \"good\" usability score, with an average SUS of 78 ± 16 (range 0-100). Younger participants reported significantly higher usability scores (p < 0.03). However, the NPS was - 15 (range - 100 to 100), indicating lower acceptability. Qualitative data supported the positive usability ratings but emphasized the need for enhancements to increase user engagement and perceived value, such as a current perceived lack of immediate benefit for many users. Their experience varied in terms of impact, with some patients suggesting an increased awareness of their symptoms while others did not notice any difference.</p><p><strong>Conclusion: </strong>Rheumatic? demonstrates good usability, particularly among younger users. Interviews revealed valuable suggestions for improvements, which could enhance overall acceptability and user satisfaction. Implementing Rheumatic? could lead to more efficient triage, potentially reducing diagnostic delays and an optimized allocation of resources. Future iterations should prioritize implementation strategies to maximize user impact and benefit.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"59"},"PeriodicalIF":2.1,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12101040/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144132125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of matrix metalloproteinase 7 and the alpha-chain of fibrinogen at baseline with response to methotrexate at 3 months in patients with early rheumatoid arthritis.","authors":"Karen Hambardzumyan, Carl Hamsten, Lucía Lourido, Saedis Saevarsdottir, Peter Nilsson, Ronald F van Vollenhoven, Per-Johan Jakobsson, Helena Idborg","doi":"10.1186/s41927-025-00509-8","DOIUrl":"10.1186/s41927-025-00509-8","url":null,"abstract":"<p><strong>Background: </strong>The identification of responders to methotrexate (MTX) would optimize the therapy of patients with early rheumatoid arthritis (eRA). Our aim was to identify protein biomarkers for the prediction of the response to MTX.</p><p><strong>Methods: </strong>We analysed patients with eRA (N = 135) from the Swedish Pharmacotherapy (SWEFOT) trial population (Trial registration number: NCT00764725). Baseline serum levels of 177 proteins with an inflammatory signature were profiled via 380 antibodies in a suspension bead array format. Protein levels were analysed for their associations with the achievement of a low 28-joint disease activity score (LDA = DAS28 ≤ 3.2) after 3 months of MTX therapy (primary outcome) or a good response according to the European Alliance of Associations for Rheumatology (EULAR) criteria (secondary outcome).</p><p><strong>Results: </strong>Multivariable analysis revealed that the serum levels of two of the 177 proteins at baseline, matrix metalloproteinase 7 (MMP-7) and the alpha-chain of fibrinogen (FGA), were significantly different between patients who did and did not achieve LDA at 3 months. Among patients with low versus high levels of either MMP-7 or FGA, 60% versus 24% and 58% versus 22%, respectively, achieved LDA (p < 0.001). Among patients with low levels of both proteins, 79% achieved LDA at 3 months, whereas only 18% of those with high levels of both proteins achieved LDA at 3 months (p < 0.001). The results were similar when a secondary outcome was used.</p><p><strong>Conclusions: </strong>Low levels of MMP-7 and FGA at baseline were associated with improved clinical outcomes in eRA patients. Validation of these results in another eRA cohort is now warranted, and if confirmed, it may facilitate clinical decision-making regarding whether to start with MTX in monotherapy or more potent alternatives.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"56"},"PeriodicalIF":2.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093799/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of intensive management on pain intensity in patients with rheumatoid arthritis and psoriatic arthritis: secondary analysis of three clinical trials.","authors":"Fowzia Ibrahim, David L Scott, Ian C Scott","doi":"10.1186/s41927-025-00493-z","DOIUrl":"10.1186/s41927-025-00493-z","url":null,"abstract":"<p><strong>Background: </strong>Understanding the impact of intensive treatment on pain in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) is crucial to informing the application of evidence-based arthritis pain care. The impact of intensive treatment on inflammatory arthritis pain has received relatively limited attention. We addressed this through a detailed secondary analysis of three trials evaluating varying intensities of disease-modifying anti-rheumatic drug treatment. We considered a range of pain outcomes of clinical relevance to patients, including the achievement of mild endpoint pain scores and clinically-meaningful pain reductions.</p><p><strong>Methods: </strong>The trials comprised MIPA in PsA, CARDERA in early RA, and TITRATE in established RA. Pain was measured using a 100-mm pain intensity visual analogue scale (VAS). The impact of intensive treatment on (a) patients achieving \"mild\" endpoint pain intensity scores (of ≤ 34), b) mean changes in pain intensity scores, and (c) patients achieving ≥ 30% reductions in pain intensity scores was evaluated using t-tests, chi-squared tests, and regression models (with the latter adjusting for relevant potential confounding variables).</p><p><strong>Results: </strong>From MIPA, CARDERA, and TITRATE 128, 379, and 258 patients had endpoint outcome data available and were included in this secondary analysis. In all trials, significantly more patients achieved mild endpoint pain intensity scores with intensive vs. control treatment (MIPA 70% vs. 42%, P = 0.003; CARDERA 71% vs. 56%, P = 0.011; TITRATE 67% vs. 50%, P = 0.008). In the two trials employing the most intensive management strategies (CARDERA; TITRATE) overall reductions in pain scores were significantly greater (6.6 to 6.8 units in adjusted linear regression models), and significantly more achieved ≥ 30% reductions in pain with intensive vs. control treatment (adjusted logistic regression models: CARDERA odds ratio [OR] 1.9, P = 0.009; TITRATE OR 2.2, P = 0.002).</p><p><strong>Conclusions: </strong>Intensive treatment is an important component of improving pain in patients with active RA and PsA. Our findings support EULAR guidance that optimising disease activity is crucial for pain control. As approximately one third of patients receiving active treatment had moderate/high endpoint pain intensity levels across trials, additional pain management strategies that complement intensive treatment are needed.</p><p><strong>Trial registration: </strong>Current Controlled Trials CARDERA ISRCTN32484878 (25/10/2000), MIPA ISRCTN54376151 (04/02/2002), and TITRATE ISRCTN70160382 (16/1/2014).</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"55"},"PeriodicalIF":2.1,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12093695/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144118868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of the Large Language Models in African rheumatology: a diagnostic test accuracy study of ChatGPT-4, Gemini, Copilot, and Claude artificial intelligence.","authors":"Yannick Laurent Tchenadoyo Bayala, Wendlassida Joelle Stéphanie Zabsonré/Tiendrebeogo, Dieu-Donné Ouedraogo, Fulgence Kaboré, Charles Sougué, Aristide Relwendé Yameogo, Wendlassida Martin Nacanabo, Ismael Ayouba Tinni, Aboubakar Ouedraogo, Yamyellé Enselme Zongo","doi":"10.1186/s41927-025-00512-z","DOIUrl":"10.1186/s41927-025-00512-z","url":null,"abstract":"<p><strong>Background: </strong>Artificial intelligence (AI) tools, particularly Large Language Models (LLMs), are revolutionizing medical practice, including rheumatology. However, their diagnostic capabilities remain underexplored in the African context. To assess the diagnostic accuracy of ChatGPT-4, Gemini, Copilot, and Claude AI in rheumatology within an African population.</p><p><strong>Methods: </strong>This was a cross-sectional analytical study with retrospective data collection, conducted at the Rheumatology Department of Bogodogo University Hospital Center (Burkina Faso) from January 1 to June 30, 2024. Standardized clinical and paraclinical data from 103 patients were submitted to the four AI models. The diagnoses proposed by the AIs were compared to expert-confirmed diagnoses established by a panel of senior rheumatologists. Diagnostic accuracy, sensitivity, specificity, and predictive values were calculated for each AI model.</p><p><strong>Results: </strong>Among the patients enrolled in the study period, infectious diseases constituted the most common diagnostic category, representing 47.57% (n = 49). ChatGPT-4 achieved the highest diagnostic accuracy (86.41%), followed by Claude AI (85.44%), Copilot (75.73%), and Gemini (71.84%). The inter-model agreement was moderate, with Cohen's kappa coefficients ranging from 0.43 to 0.59. ChatGPT-4 and Claude AI demonstrated high sensitivity (> 90%) for most conditions but had lower performance for neoplastic diseases (sensitivity < 67%). Patients under 50 years old had a significantly higher probability of receiving a correct diagnosis with Copilot (OR = 3.36; 95% CI [1.16-9.71]; p = 0.025).</p><p><strong>Conclusion: </strong>LLMs, particularly ChatGPT-4 and Claude AI, show high diagnostic capabilities in rheumatology, despite some limitations in specific disease categories.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"54"},"PeriodicalIF":2.1,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12083132/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144085866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An atypical manifestation of Giant cell arteritis (GCA): constitutional symptoms & lingual ulcer in a 78-Year-Old male with negative temporal artery biopsies.","authors":"James Gow, David Roofeh","doi":"10.1186/s41927-025-00505-y","DOIUrl":"https://doi.org/10.1186/s41927-025-00505-y","url":null,"abstract":"<p><strong>Background: </strong>Giant cell arteritis (GCA) is a large vessel vasculitis characterized by granulomatous inflammation classically affecting the carotid artery branches. GCA most often presents with one or more classic clinical features which include headache, jaw claudication, temporal scalp tenderness, and polymyalgia rheumatica. In a minority of cases, GCA can adopt an \"occult\" presentation (i.e., failure to thrive in the setting of unexplained inflammation) where vascular manifestations affect vascular beds, such as lingual ulceration, not amenable to biopsy. While the diagnosis of GCA is often supported by temporal artery biopsy or imaging studies, such as temporal artery ultrasound or magnetic resonance angiography, these techniques are known to have limited sensitivity. As a result, there is the potential for GCA to be misdiagnosed where it presents both in the absence of classic clinical manifestations and without clear diagnostic evidence by imaging or histopathology.</p><p><strong>Case presentation: </strong>A 78-year-old male presented to rheumatology on the inpatient consult service with unexplained headaches, failure to thrive, and persisting elevated acute phase reactants. He was admitted for unexplained fevers three times in as many months, with an unrevealing infectious and malignancy workup. His past medical history was remarkable for a shallow right lateral tongue ulcer that was non-healing despite weeks of acyclovir treatment. Two bitemporal artery ultrasounds did not suggest features of GCA and subsequent temporal artery biopsies failed to show healing or active arteritis. The patient was started on empiric corticosteroids tapered to discontinue over six months in conjunction with tocilizumab. He had rapid normalization of inflammatory markers (prior to tocilizumab initiation), anemia of chronic inflammation, and correction of his serum Na + without need for ongoing fluid restriction. Clinically, his headaches and unexplained weight loss improved and his serial exams showed complete resolution of his tongue ulcer, suspected to be end-organ damage from GCA.</p><p><strong>Conclusions: </strong>Although the hospitalist service suspected GCA in this elderly patient with headaches, failure to thrive, recurrent fever of unknown origin, and elevated inflammatory markers, they were deterred from this diagnosis by repeat negative bitemporal artery ultrasounds and negative biopsies. This case demonstrates the need to survey for atypical vascular beds of GCA involvement, even in the presence of negative imaging and biopsy results.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"53"},"PeriodicalIF":2.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12080050/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Influence of socioeconomic status on access to temporal artery biopsy and rates of biopsy positivity in patients with suspected giant cell arteritis.","authors":"Suellen Anne Lyne, Susan Lester, Oscar Kenneth Russell, Carlee Deanne, Kathryn Dyer, Jem Ninan, Ernst Michael Shanahan, Catherine Louise Hill","doi":"10.1186/s41927-025-00503-0","DOIUrl":"https://doi.org/10.1186/s41927-025-00503-0","url":null,"abstract":"<p><strong>Background: </strong>Data regarding the relationship between socioeconomic status (SES) and incidence of Giant Cell Arteritis (GCA) is conflicting. No previous studies have explored whether SES influences the likelihood of undergoing temporal artery biopsy (TAB). The aim of this study was to determine whether SES influences access to TAB and rate of biopsy positivity in those with suspected GCA.</p><p><strong>Methods: </strong>This retrospective study included consecutive patients who underwent TAB examined at SA Pathology between 2017 and 2022; age ≥ 50 years and resident in South Australia (SA). Patients' addresses were used to identify precise geographical areas. Area-level SES was determined using Index of Relative Socioeconomic Advantage and Disadvantage (IRSAD) scores, derived from 2016 Census data. IRSAD scores were grouped into population quintiles and analysed by multinomial regression.</p><p><strong>Results: </strong>626 participants were included, of whom 155 (25%) were TAB positive. Those with positive TAB were older (76 v 72 years) and a smaller proportion were female (63% v 71%). There was a shift towards a lower SES for patients undergoing TAB, with 161 (26%) in the lowest quintile and 107 (17%) in the highest (p_linear<0.001). However, SES was not associated with TAB positivity; 34/161 (21%) participants were TAB positive in the lowest quintile compared to 33/107 (31%) in the highest (p = 0.19).</p><p><strong>Conclusion: </strong>SES did not influence incidence of GCA. However, those from lower SES population quintiles were more likely to undergo TAB at a State Pathology service provider. Encouragingly, this suggests there is no issue with access to TAB in SA based on SES.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"52"},"PeriodicalIF":2.1,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12076884/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144075998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Psychosocial factors associated with physical activity, weight management, and sleep in adults with hip and knee osteoarthritis: a systematic review.","authors":"Britt van Dongen, Amber Ronteltap, Bastiaan Cijs, Corelien Kloek, Catherine Bolman, Rik Crutzen","doi":"10.1186/s41927-025-00506-x","DOIUrl":"https://doi.org/10.1186/s41927-025-00506-x","url":null,"abstract":"<p><strong>Background: </strong>Osteoarthritis (OA) is a chronic disease primarily affecting older adults, mainly impacting the hip and knee joints. The increasing prevalence of OA contributes to rising healthcare demands and costs. Current OA treatment guidelines emphasize the importance of self-management education and guidance, particularly in promoting physical activity and weight management. In addition, improving sleep is crucial for managing OA. Developing effective self-management interventions necessitates a comprehensive understanding of the factors that facilitate these behaviors. Especially for changing health behaviors, it is important to focus on psychosocial factors. Therefore, this systematic review aimed to identify the psychosocial factors associated with physical activity, weight management, and sleep in adults with hip and/or knee OA.</p><p><strong>Methods: </strong>Five databases (PubMed, Embase, CINAHL, PyschINFO, Web of Science) were searched for observational studies reporting statistics on the association between psychosocial determinants and physical activity, weight management, or sleep in people with OA. The methodological quality was assessed using the Quality Assessment Tool for Observational Studies of the National Heart, Lung, and Blood Institute. After screening 5,812 articles, 31 studies were included for analysis.</p><p><strong>Results: </strong>The results showed that intention, self-efficacy, and willpower beliefs were positively associated with physical activity. Kinesiophobia, pain catastrophizing and pain-related fear were negatively associated with physical activity. Depressive symptoms, negative affect, pain catastrophizing, and low willpower beliefs were associated with poor weight management. Anxiety, depression, pain anxiety, and post-traumatic stress disorder were related to poor sleep behavior.</p><p><strong>Conclusions: </strong>This review enhances the understanding of the psychosocial factors underlying physical activity, weight management and sleep in OA. These insights are valuable for developing tailored behavior change interventions aimed at improving physical activity, weight management and sleep in patients with hip and/or knee OA. Future research is warranted to gain more in-depth insights, particularly through longitudinal studies and further research into the psychosocial determinants of sleep, as current literature in this area is limited.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"51"},"PeriodicalIF":2.1,"publicationDate":"2025-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12063410/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microvascular abnormalities between anti-TIF1-γ-associated dermatomyositis with and without malignancy.","authors":"Sehreen Mumtaz, Jordan Phillipps, Megan M Sullivan, Maximiliano Diaz-Menindez, Benjamin Wang, Vikas Majithia, Emily Craver, Florentina Berianu","doi":"10.1186/s41927-025-00504-z","DOIUrl":"https://doi.org/10.1186/s41927-025-00504-z","url":null,"abstract":"<p><strong>Background: </strong>Dermatomyositis (DM) is an immune-mediated myopathy characterized by proximal muscle weakness, inflammation, and cutaneous manifestations. Up to 25% of DM patients have an associated malignancy. Those with cancer-associated DM often face worse prognoses, poorer treatment responses, and reduced survival rates. Interestingly, anti TIF1γ-positive DM patients are notably at increased risk for malignancy, yet the underlying mechanisms and clinical correlation remain poorly understood. Nailfold video capillaroscopy (NVC) is a safe, non-invasive method for assessing vascular abnormalities, previously explored in various DM subsets but not specifically in anti TIF1γ-positive DM patients with malignancy. This study aims to characterize NVC findings in anti-TIF1γ-positive DM and assess their clinical relevance, particularly in malignancy-associated cases.</p><p><strong>Methods: </strong>A retrospective review at Mayo Clinic, Jacksonville from January 1st, 2010 to May 16th, 2024 was conducted. 19 cases with anti TIF1γ-positive DM and 18 idiopathic inflammatory myopathy controls were included.</p><p><strong>Results: </strong>We observed anti TIF1γ-positive DM cases to have significantly increased capillary density loss and higher microhemorrhages (p = 0.057). Cases also had higher frequencies of dilated capillaries, capillary ramifications, and capillary disorganization. Although no statistically significant differences in NVC pattern were identified in cancer vs. non-cancer anti TIF1γ-positive DM, there were greater hemorrhages and ramifications noted in the cancer anti TIF1γ-positive subset.</p><p><strong>Conclusion: </strong>This study investigated NVC differences among anti TIF1γ-positive DM with malignancies versus idiopathic inflammatory myopathy controls. Our findings indicate promising microvascular differences with a potential for predicting cancer development that warrant further exploration in larger studies.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"50"},"PeriodicalIF":2.1,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12057095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143961664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating exo-miRNA-27a-5p is a novel biomarker of the tofacitinib treatment response in rheumatoid arthritis.","authors":"Jiwei Zhao, Tianjun Zhu, Qiu Liao, Jijia Sun, Fuqun Liu","doi":"10.1186/s41927-025-00502-1","DOIUrl":"https://doi.org/10.1186/s41927-025-00502-1","url":null,"abstract":"<p><strong>Background: </strong>Effective biological markers able to monitor the response of Janus kinase inhibitor (JAKi) are lacking. Exosomal microRNAs (exomiRNAs) can alter their expression during treatment and are ideal biomarkers for therapeutic interventions. In this study, we explored potential biomarkers for monitoring tofacitinib treatment response in patients with RA.</p><p><strong>Methods: </strong>Peripheral blood mononuclear cells (PBMCs) were collected from 35 healthy controls (HCs) and 74 patients with methotrexate (MTX)-resistant new-onset RA. We analyzed the profiles of exomiRNAs using next-generation sequencing (NGS) and verified them using quantitative real-time polymerase chain reaction (qRT-PCR). The functional roles of the selected exomiRNAs were analyzed using bioinformatics tools. Potential exomiRNAs were validated in MTX-resistant RA patients treated with tofacitinib for 3 months.</p><p><strong>Results: </strong>Fifty-six differentially expressed exomiRNAs were identified. High expressions of the exo-(miR-548ah-3p, miR-378 g, miR-27a-5p, and miR-30c-2-3p) were validated by qRT-PCR. Enrichment analysis indicated that these exomiRNAs may regulate immune cells and mediate immune responses. Exo-miR-27a-5p levels significantly decreased after tofacitinib treatment (p < 0.0001) and showed a strong correlation with the DAS28, RF and ESR. Receiver operating characteristic curve analysis showed that changes in the expression levels of exo-miR-27a-5p were significantly correlated with tofacitinib therapy (AUC = 0.92, p < 0.0001).</p><p><strong>Conclusions: </strong>This study suggests that circulating exo-miR-27a-5p is a novel non-invasive biomarker to monitor the response to tofacitinib treatment.</p>","PeriodicalId":9150,"journal":{"name":"BMC Rheumatology","volume":"9 1","pages":"49"},"PeriodicalIF":2.1,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12036121/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143975006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}